Merck to buy VC-backed OncoImmune for $425m

Merck has agreed to acquire OncoImmune, a clinical-stage biopharmaceutical company, for $425 million in cash.

To read this article, you need to sign in.


You should only be asked to sign in once. Not the case? Click here


Register now to read this article and more for free.

Share this